Physician profile
Stephen Ramirez
NPI 1184716524
$6,638.33
in general payments reported to CMS, 2019-2025
28 companies · $919 in 2025
The $919 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $905 · 2020: $654 · 2021: $1,337 · 2022: $1,036 · 2023: $775 · 2024: $1,011 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,705.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,270.59 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Esperion Therapeutics, INC. | $666.56 | 2021-2023 | Nexletol |
| Lilly USA, LLC | $558.75 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Phathom Pharmaceuticals, INC. | $487.28 | 2024-2025 | Voquezna |
| Abbvie INC. | $463.05 | 2021-2024 | |
| Axsome Therapeutics, INC. | $425.83 | 2024-2025 | Auvelity, Sunosi, Symbravo |
| Allergan, INC. | $417.23 | 2019-2020 | |
| Abbott Laboratories | $307.47 | 2019-2024 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $253.48 | 2019-2023 | Ajovy |
| Astrazeneca Pharmaceuticals Lp | $252.39 | 2020-2023 | Fasenra, Breztri, Farxiga |
| Amarin Pharma, INC. | $244.93 | 2019-2022 | |
| Lundbeck LLC | $224.28 | 2021-2025 | Vyepti |
| Bayer Healthcare Pharmaceuticals INC. | $197.85 | 2023 | |
| Pfizer INC. | $156.17 | 2019-2025 | |
| Si-Bone, INC. | $152.07 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $135.35 | 2021 | |
| Bausch Health US, LLC | $85.22 | 2019-2025 | Aplenzin, Wellbutrin |
| Boston Scientific Corporation | $85.12 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.21 | 2020-2025 | Trintellix |
| Ardelyx, INC. | $37.06 | 2024 | Ibsrela |
| Phadia US INC. | $31.26 | 2024 | Immunocap |
| Genentech USA, INC. | $27.21 | 2020-2021 | |
| Organon LLC | $25.25 | 2025 | |
| Inspire Medical Systems, INC. | $19.06 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $17.35 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.79 | 2019 | |
| Ibsa Pharma INC. | $13.33 | 2023 | Tirosint, Licart |
| Eisai INC. | $13.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.